Another PARP inhibitor showing promise

PARP inhibitors are unique molecules targeting only the PARP enzyme in BRCA 1/2 mutated cells, they are generally well tolerated as compared to chemotherapy. In this year at San Antonio Breast Cancer Symposium, the EMBRACA trial results were presented in abstract form.

The talazoparib arm patients reported better quality of life score as well as there was a significant delay in the time to deterioration

 

Continue reading “Another PARP inhibitor showing promise”